About

Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using big data and AI to accelerate treatments for rare diseases. He is the Co-Founder and Chief Executive of Healx, the AI-powered, patient-inspired tech company, accelerating the discovery and development of rare disease treatments at scale. In 2019, Healx raised $56 million in Series B funding and was listed in Tech Nation’s Future Fifty cohort. In 2020, the company won 5 prizes at the CogX Awards including Grand Jury Prize and Best AI Product and was listed in CB Insights Digital Health 150.

As CEO of Healx, Tim has been listed in The Sunday Times Maserati 100 list of entrepreneurs in 2019, was was named as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020, and was selected as member of the Forbes Technology Council in 2022.

Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease. Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.

Dr Anthony Hall graduated from King’s College London with first class joint honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital. He has over 25 years of drug development with ten years working on rare diseases.

As CMO at Healx Tony will be responsible for progressing the company’s rare disease drug candidates through the clinic. He will also oversee relationships with regulatory bodies at a global level.

Prior to joining Healx, Tony worked as CMO at Aparito and as Therapeutic Area Head of Orphan Drugs at Mereo BioPharma. He previously co-designed the development programme for DevelopAKUre, an FP7-funded project to redevelop nitisinone for the treatment of the rare metabolic disease, alkaptonuria (AKU). He is currently Trustee of Findacure and a member of the Scientific Advisory Board at the patient group charity Duchenne UK. He is also co-editor of The Patient Group Handbook for rare diseases.

Over the last 30+ years, Neil’s career has seen him progress more than 10 drugs to patients and he’s led a number of drug discovery projects in areas of cardiovascular, neurology, inflammation and oncology among others.

For 15 years, Neil was Senior Vice President of Biology at Astex Pharmaceuticals, helping the company establish itself at the forefront of drug discovery by leading the biology and pre-clinical teams to deliver two new cancer drugs (Kisqali; ribociclib and Balversa; erdafitinib in partnership with Novartis and Janssen respectively) to market. Before that, he was Director of the Immunology Platform at GlaxoSmithKline (GSK).

Neil is also Deputy Chair of the UK MRC DPFS panel and Chair of the MRC CLD/ADI committee, has authored more than 40 publications and patents and sits on the advisory boards of several scientific institutions in the UK.

Neil received his doctorate in Biochemistry from King’s College London.

Dr Bruce Bloom is the founder and former CEO of Cures Within Reach, a leading global non-profit saving lives by unleashing the untapped potential of human approved drugs, devices, diagnostics and nutraceuticals, testing new uses for them to quickly deliver safe and affordable treatments and cures for diseases that have no currently effective therapy.

Bruce envisioned and created CureAccelerator®, the first online redevelopment research collaboration platform, to bring together clinicians, researchers, funders, and industry to create and conduct proof of concept redevelopment clinical trials. Dr Bloom is an Ashoka Social Entrepreneur Fellow, the Patient Advisory Board Chair for the Institute for Translational Medicine, board member of the Drug Discovery Center and Chair of the Cancer Center Advancement Advisory Boards at the University of Illinois Chicago, member of the Vanderbilt Institute for Clinical and Translational Research External Advisory Board, and is on the Science Advisory Boards of Rediscovery Life Sciences, the Dr. Ralph and Marian Falk Medical Research Trust Awards Programs, the Findacure Fundamental Disease Charity, the Rare Disease Research Hub of the Westchester Biotech Project, OneThree Biotech, and Cures Within Reach for Cancer, and is a member of the editorial board of ASSAY and Drug Development Technologies.

Gillian Bonthron brings more than 20 years experience in financial leadership and the capital markets including fundraising, mergers and acquisitions and strategic finance in both private equity and PLC environments.Prior to joining Healx as Chief Financial Officer, Gillian held a number of senior finance positions in the biotech and support services industries including Perspectum Limited, Mitie Group PLC, Connect Group PLC and KPMG.Gillian is a member of the Institute of Chartered Accountants for Scotland and holds a first class honours degree in Accountancy and Business Law.

Eugenia is an experienced biopharma leader, with over 25 years' experience in a range of national and international roles including General Manager (UK, NL) and VP of Commercial Operations. During her career, Eugenia has been responsible for developing commercial and market access strategies, leading strategic and operational marketing, and building business excellence.

She has worked in a wide range of therapeutic indications, across the product life cycle from launch-planning to patent expiry and beyond, and has covered different archetype markets both in Europe and emerging markets.

Eugenia holds an MSc in Molecular Biology and an Executive MBA.

Laura has over 20 years' experience in international HR roles across a variety of industries including media, sales and tech. She has worked in HR, recruiting, employee engagement, organisational change and diversity roles in both blue chip and start-up companies and is passionate about helping companies scale effectively. Mostly recently Laura led the HR function at a fintech in the blockchain space. Previously she led EMEA recruitment teams at Google to help scale the company during a period of incredible growth.

At Healx she is responsible for building effective people programs that enable us to attract great talent and drive the growth and development of our people and the business.

Mark is an experienced business development leader. As the Global Head of Business Development and Licensing, he is responsible for leading Healx's strategic and business development initiatives.

Prior to joining Healx, Mark was the Global Head of Business Development at Acrotech Biopharma where he successfully closed multiple transactions to help build the company from the start. Previously, he has also worked in Business Development at Bayer and held various positions in the pharmaceutical industry.

Mark has a Doctor of Pharmacy degree, Masters in Business Administration and post-doctoral fellowship training from Rutgers University.